Alessandro Minelli's research while affiliated with Università Campus Bio-Medico di Roma and other places

... Rego displays more symptomatic adverse events such as asthenia, hand-foot syndrome, and skin reactions, while TFD/TPI-related adverse effects are generally more asymptomatic (neutropenia, anemia) [16]. Therefore, TFD/TPI is more often prescribed in older patients or in patients with worse performance status [16,17]. ...

... The best protocols for the administration of T and R in patients with advanced disease, the identification of subpopulations that might benefit from vital treatment with these drugs, and the identification of those subpopulations that might benefit from treatment with these drugs vs. the best supportive therapy alone are all questions that have yet to be resolved [29][30][31][32][33][34][35]. Furthermore, T and R have not been directly compared to one another, and it is uncertain which agent should be given first [36][37][38][39][40][41]. This multi-institutional retrospective study aimed to assess the effect of R and T, administered sequentially or not, on clinical outcomes and safety in patients with mCRC resistant to conventional chemotherapies. ...

... GISTs mostly occur among middle-aged individuals between 60 and 65 years and a minority of children and young adults [3], with a slightly higher incidence in males [2]. They account for around 20% of soft tissue sarcomas [4], with an incidence of 10-15 cases per million worldwide, with the highest incidence rate being reported from China (Hong Kong and Shanghai areas) [5]. Most GISTs harbor oncogenic mutations in the receptor tyrosine kinase (KIT; 65-80%) or in the related platelet-derived growth factor receptor a (PDGFRA; 5-10%), which controls the tyrosine kinase receptors and causes constitutional activation, leading to tumor growth of cells [6,7]. ...

... Here, we report data from a case series affected by high-risk stage III and stage IV CRC and tested for RAS and BRAF mutation, treated at our Medical Oncology Unit. The analysis of KRAS, NRAS (codons 12,13, 59, 61, 117, 146), and BRAF (codon 600) hotspot variants was performed in 161 CRC tumors from August 2018 to September 2021 and revealed three (1.8%) patients showing mutations in both KRAS and BRAF (V600E), including two cases with earlier CRC and one with metastatic disease. ...

... Aneuploid CTCs have also been identified in STS patients, in a pilot study in 2020; FISH analysis has been performed and CTCs were identified in all four metastatic STS patients tested, with a median value of 4 per 7 mL of blood [235]. In silico evidence using data from STS cohort of The Cancer Genome Atlas Project and the validated Aneuploidy Score confirmed the prognostic role of aneuploidy in mesenchymal cancers, with a significantly worse PFS and OS in the group with a high DNA aneuploidy, independently of the histology of the tumor. ...

... In symptomatic cases, chemotherapy and tyrosine kinase inhibitors are used, though some cases result in surgery [2,4]. Nevertheless, even after treatment, desmoid tumour recurrence is common, ranging from 24 to 77% in extremities [2,8]. Recurrence is favoured by trauma, such as in surgery, and stands at around 25 to 60% at 5 years post-treatment [2,8]. ...

... In 21 studies, the tissue samples were retrieved retrospectively . Two studies collected tissue samples at time of surgical resection [41,42], and in nine studies, there was no need for tissue collection because the mutation status of genes of interest had already been analyzed as part of diagnostic reasons [43][44][45][46][47][48][49][50][51]. Most tissue samples used in the studies (n = 24) were formalin-fixed paraffin-embedded (FFPE), while the remaining eight studies used fresh frozen tumor samples [22,31,32,34,38,[40][41][42]. ...

... As more advanced therapy strategies have been established for reducing the mortality of PC, we require more predictive tools for oncological outcomes [14]. In other words, predicting the oncological outcomes of this disease based on the prognostic factors plays a crucial role in increasing PC survival by detecting the factors contributing to worsening the patients' outcomes at earlier stages [15]. ...